What is the Modified Simple Screening Instrument for Substance Abuse (MSSI‑SA) scale, including its scoring range, interpretation thresholds, and recommended follow‑up actions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

MSSI-SA Scale Information

The Modified Simple Screening Instrument for Substance Abuse (MSSI-SA) is not described in the provided evidence. The evidence discusses the Simple Screening Instrument for Substance Abuse (SSI-SA) but does not contain information about a "Modified" version (MSSI-SA).

What the Evidence Does Show: SSI-SA (Not MSSI-SA)

The Simple Screening Instrument for Substance Abuse (SSI-SA) is a validated self-report screening tool with the following characteristics 1:

Scoring and Interpretation

  • Cutoff score: ≥4 indicates presence of substance abuse problem
  • Scores range from 0 upward (specific maximum not detailed in evidence)
  • The tool demonstrates excellent internal consistency (0.85)

Performance Characteristics

  • Sensitivity: 82% - correctly identifies 82% of individuals with substance abuse problems
  • Specificity: 90% - correctly identifies 90% of individuals without substance abuse problems 1

Clinical Utility

The SSI-SA effectively distinguishes between individuals with and without substance abuse needs and correlates significantly with functional impairment in daily living 1.

Alternative Validated Screening Tools

Since the MSSI-SA is not documented in the evidence, consider these well-validated alternatives for substance abuse screening:

For General Adult Populations

Drug Abuse Screening Test-10 (DAST-10) 2:

  • 0 points = low risk
  • 1-3 points = moderate risk → monitor and reassess
  • >3 points = substance abuse or dependence → requires intervention
  • Sensitivity: 90-100%; Specificity: 77%

For Adolescent Populations

CRAFFT 2.1+N 3: Ten-item questionnaire assessing past-year use, motivations, hazardous use, and consequences with clearly demarcated clinical cutoffs

S2BI (Screening to Brief Intervention) 3: Queries past-year frequency for nicotine, cannabis, and prescription opioids with built-in brief intervention recommendations

Common Pitfall

Do not confuse the SSI-SA with the SASSI-3 (Substance Abuse Subtle Screening Inventory-3), which is a different instrument with variable psychometric properties across populations 4.

References

2
Guideline

a primary care approach to substance misuse.

American family physician, 2013

Related Questions

How should a 10-year-old boy with two episodes of diarrhea, mild abdominal pain, and no fever be managed?
Should a 1.1 cm ovarian follicle be followed up with repeat ultrasound?
How should I manage a 10-month-old infant with a rectal temperature of 100.6 °F and two episodes of vomiting?
What is the recommended evaluation and management for a 10-year-old male with pubic pain, intermittent dysuria for 2–3 months, decreased appetite, and urine specific gravity of 1.015?
Why does an 11‑day‑old neonate who drinks only 45–55 mL of a prescribed 70 mL per feed because of fatigue stop feeding, and what further diagnostic work‑up is indicated?
What is the appropriate ertapenem dose, dosing frequency, and treatment duration for an uncomplicated urinary tract infection in a patient with normal renal function?
Should I continue to monitor the right eye after a fall that caused periorbital bruising and conjunctival redness?
Can methylene blue be taken together with low‑dose naltrexone (LDN)?
What is Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)?
What is the clinical significance and recommended management for a prostate measuring 5.5 cm in greatest dimension?
What oral contraceptive can a 37-year-old woman with epilepsy who is taking levetiracetam (Keppra) use without affecting her levetiracetam therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.